Related Experiment Videos
Antibody variable region interactions with Protein A: implications for the development of generic purification
Sanchayita Ghose1, Martin Allen, Brian Hubbard
1Purification Process Development, Amgen Incorporation, Seattle, Washington, USA.
Biotechnology and Bioengineering
|October 6, 2005
Summary
This study explores Protein A chromatography for antibody separation. An engineered Protein A ligand mitigates variable region interactions, allowing a single elution pH and reducing aggregation for faster therapeutic development.
Area of Science:
- Biochemistry
- Chemical Engineering
- Biotechnology
Background:
- Protein A chromatography is a key method for antibody purification.
- Variability in elution pH complicates generic separation processes for diverse antibodies.
- Understanding factors influencing elution pH is crucial for process optimization.
Purpose of the Study:
- To investigate the causes of elution pH differences for various antibodies during Protein A chromatography.
- To evaluate an engineered Protein A ligand for improved generic separation.
- To assess the impact of the engineered ligand on low pH-induced aggregation.
Main Methods:
- Utilized a wide range of antibodies, including IgG subclasses, fragments, and Fc-fusion proteins.
- Employed complementary techniques to analyze elution pH determinants.
- Compared traditional Protein A chromatography with a resin using an engineered B domain ligand.
Main Results:
- Variable region interactions significantly influence elution pH with traditional Protein A materials, especially for VH3 subfamily antibodies.
- The engineered Protein A ligand (Protein A B domain) mitigates variable region interactions.
- A single elution pH was achievable for a range of antibodies using the engineered ligand.
- Moderated elution conditions minimized low pH-induced aggregation.
Conclusions:
- Variable region interactions are a primary driver of elution pH variability in standard Protein A chromatography.
- An engineered Protein A ligand offers a solution for generic antibody separation by enabling a single, consistent elution pH.
- This approach simplifies process development and reduces aggregation issues, accelerating the timeline for therapeutic manufacturing.